A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
← catalyst calendarNCT07116889 · readout ≤ 285 d
Sponsored by Generate Biomedicines (industry) · GENB — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
156estimated
Sites
13
Countries
Germany, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-12 | actual | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Asthma
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
- Biological: GB-0895 (SC)
- Biological: GB-0895 (SC)
- Drug: Placebo (SC)
- Drug: Placebo (SC)
Primary outcome
what the primary-completion date above is the date OFNumber of participants with treatment related adverse events as assessed by CTCAE 5.0
measured Day 1 to Day 500
Permalink · GENB's whole pipeline · Catalyst calendar · Every registered study · What changed